Cytokinetics Files 8-K
Ticker: CYTK · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing
Related Tickers: CYTK
TL;DR
Cytokinetics filed an 8-K on Aug 31, 2025. Details TBD.
AI Summary
Cytokinetics, Inc. filed an 8-K on September 3, 2025, reporting other events and financial statements as of August 31, 2025. The filing does not contain specific details about the nature of these events or financial figures within the provided text.
Why It Matters
This filing indicates a regulatory update from Cytokinetics, Inc., which may contain important information for investors regarding company events or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting events and exhibits, with no immediate indication of significant negative developments.
Key Players & Entities
- Cytokinetics, Inc. (company) — Registrant
- August 31, 2025 (date) — Date of earliest event reported
- September 3, 2025 (date) — Filing Date
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific events are being reported in this 8-K filing?
The provided text indicates the filing is for 'Other Events' and 'Financial Statements and Exhibits' but does not detail the specific events.
What is the fiscal year end for Cytokinetics, Inc.?
The fiscal year end for Cytokinetics, Inc. is December 31.
What is the Commission File Number for Cytokinetics, Inc.?
The Commission File Number for Cytokinetics, Inc. is 000-50633.
What is the business address of Cytokinetics, Inc.?
The business address of Cytokinetics, Inc. is 350 Oyster Point Boulevard, South San Francisco, California 94080.
What is the filing date of this 8-K report?
This 8-K report was filed as of September 3, 2025.
Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 13.8 · Accepted 2025-09-02 17:34:38
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
Filing Documents
- cytk-20250831.htm (8-K) — 41KB
- cytk-ex99_1.htm (EX-99.1) — 80KB
- img114956760_0.jpg (GRAPHIC) — 23KB
- img114956760_1.jpg (GRAPHIC) — 117KB
- 0000950170-25-112570.txt ( ) — 416KB
- cytk-20250831.xsd (EX-101.SCH) — 24KB
- cytk-20250831_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On August 31, 2025, Cytokinetics, Incorporated announced that additional data related to aficamten were presented at the European Society of Cardiology Congress 2025 in Madrid, Spain, including a pre-specified analysis of the effect of aficamten on cardiac structure and function from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM), which was simultaneously published in the Journal of the American College of Cardiology, as well as a Late Breaking Clinical Science presentation related to the incidence and impact of atrial fibrillation (AF) associated with aficamten, which was simultaneously published in Heart Rhythm. The full text of the press release issued in connection with this announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. 99.1 Press Release dated August 31, 2025. 104 The cover page of this report has been formatted in Inline XBRL
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: September 2, 2025 By: /s/ John Faurescu SVP, Deputy General Counsel & Secretary